Skip to main content

Table 2 Three years evolution in GnRHa treated and untreated patients with CPP

From: Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment

 

Baseline

1 yr

2 yrs

3 yrs

 

Treated

Untreated

Treated

Untreated

Treated

Untreated

Treated

Untreated

After Tx

CA (yr)

7.3 ± 1.5

7.7 ± 0.7

8.3 ± 1.5

8.7 ± 0.9

9.2 ± 1.5

9.6 ± 0.7

10.1 ± 1.5

10.7 ± 1.2

11.04 ± 0.4

Weight (z-score)

1.4 ± 0.7

1.2 ± 0.8

1.4 ± 0.6

1.3 ± 0.8

1.3 ± 0.9

1.2 ± 0.7

1.6 ± 0.6*

0.9 ± 0.5

0.8 ± 0.9

BMI (z-score)

1.2 ± 0.9

1 ± 0.8

1.2 ± 0.7

1.1 ± 0.8

1.1 ± 1

1 ± 0.7

1.3 ± 0.8

0.7 ± 0.5

0.7 ± 0.9

Ob/over (%)

79.3

50

65.4

50

65.4

50

81.8

40

40

Obesity (%)

24.1

25

26.9

25

23.1

25

45.5

0

20

Overweight (%)

55.2

25

38.5

25

42.3

25

36.4

40

20

Glycemia (mg/dl)

73.1 ± 9.1

74 ± 7.6

79.6 ± 8.9

88.6 ± 6.5

76 ± 10.1

84.3 ± 11.7

84.4 ± 5.3

80 ± 2.6

81 ± 18.4

Total-C (mg/dl)

156 ± 31.5

167.6 ± 35.7

172.1 ± 34.8

146.5 ± 42.3

152.8 ± 38.6

177.3 ± 23.9

159.2 ± 26.5

171.7 ± 39.1

167.3 ± 19.4

LDL-C (mg/dl)

96.6 ± 38.1

99.5 ± 16.3

108.1 ± 19.1

71.3 ± 24.1

92.9 ± 30.5

112.5 ± 7.8

100.2 ± 22.8

128.8 ± 13.9

122.5 ± 2.1

HDL-C (mg/dl)

43.8 ± 9

52 ± 7.1

35 ± 10.1

37.3 ± 9

48.5 ± 12.8

37 ± 4.2

43.8 ± 14

45.5 ± 2.1

44.5 ± 14.9

TRG (mg/dl)

83.3 ± 36.2

115.8 ± 78.5

80.9 ± 30.7

90.8 ± 33.7

79.9 ± 46.5

117 ± 66.8

83.3 ± 52.7

98.5 ± 37.5

64 ± 31.1

TRG/HDL-C ratio

2.1 ± 0.8

3 ± 1.5

2.5 ± 1

2.4 ± 0.5

1.7 ± 1.2

2.9 ± 2.2

1.9 ± 1.3

2.2 ± 0.9

2 ± 0.8

  1. Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for age and sex.
  2. After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, obesity and overweight rate; Total-C, total cholesterol; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerides.
  3. *p 0.02, treated vs. untreated at 3 years of follow up.